Javier DÃ-ez Domingo

List of Publications by Year
in descending order

150 papers	5,679 citations	126907 33 h-index	95266 68 g-index
179 all docs	179 docs citations	179 times ranked	5478 citing authors

#	Article	IF	Citations
1	Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. New England Journal of Medicine, 2015, 372, 2087-2096.	27.0	1,040
2	Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. New England Journal of Medicine, 2016, 375, 1019-1032.	27.0	752
3	Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules. JAMA - Journal of the American Medical Association, 2012, 307, 573-82.	7.4	247
4	Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. The Lancet Global Health, 2020, 8, e497-e510.	6.3	235
5	InvasiveHaemophilus influenzaeDisease, Europe, 1996â€“2006. Emerging Infectious Diseases, 2010, 16, 455-463.	4.3	186
6	A cost benefit analysis of routine varicella vaccination in Spain. Vaccine, 1999, 17, 1306-1311.	3.8	94
7	Do We Know When, What and For How Long to Treat?. Pediatric Infectious Disease Journal, 2012, 31, e78-e85.	2.0	93
8	Antibiotic Use in Children â€“ A Cross-National Analysis of 6 Countries. Journal of Pediatrics, 2017, 182, 239-244.e1.	1.8	90
9	A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus GardasilÂ® in 9â€“15-Year-Old Girls. Pediatric Infectious Disease Journal, 2015, 34, 992-998.	2.0	89
10	Effectiveness of MF59â„¢-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine, 2007, 25, 7313-7321.	3.8	81
11	Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infectious Diseases, 2014, 14, 544.	2.9	76
12	Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine, 2004, 23, 283-289.	3.8	65
13	Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 Years. Pediatric Infectious Disease Journal, 2010, 29, e35-e46.	2.0	57
14	Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines â€“ Multi-country assessment. Vaccine, 2018, 36, 6202-6211.	3.8	53
15	Immunogenicity and Safety of Three Doses of a Bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) Meningococcal Outer Membrane Vesicle Vaccine in Healthy Adolescents. Vaccine Journal, 2007, 14, 65-73.	3.1	51
16	Population-based Analysis of Bronchiolitis Epidemiology in Valencia, Spain. Pediatric Infectious Disease Journal, 2016, 35, 275-280.	2.0	51
17	Prevention of vaccine-matched and mismatched influenza in children aged 6â€“35 months: a multinational randomised trial across five influenza seasons. The Lancet Child and Adolescent Health, 2018, 2, 338-349.	5.6	51
18	Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 152-160.	1.3	49

#	Article	IF	Citations
19	Risk and impact of herpes zoster on patients with diabetes: A population-based study, 2009â€“2014. Human Vaccines and Immunotherapeutics, 2017, 13, 2606-2611.	3.3	46
20	Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review. Dermatology and Therapy, 2021, 11, 1119-1126.	3.0	43
21	A Randomized, Multicenter, Open-Label Clinical Trial to Assess the Immunogenicity of a Meningococcal C Vaccine Booster Dose Administered to Children Aged 14 to 18 Months. Pediatric Infectious Disease Journal, 2010, 29, 148-152.	2.0	42
22	Herpes zoster surveillance using electronic databases in the Valencian Community (Spain). BMC Infectious Diseases, 2013, 13, 463.	2.9	42
23	Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain. Vaccine, 2017, 35, 3342-3346.	3.8	42
24	Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the valencian community of Spain. BMC Infectious Diseases, 2011, 11, 302.	2.9	41
25	Effectiveness of the 2010â€“2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: A caseâ€“case comparison, case-control study. Vaccine, 2012, 30, 5714-5720.	3.8	41
26	The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. Clinical Infectious Diseases, 2022, 74, 1459-1467.	5.8	41
27	Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications. Epidemiology and Infection, 2010, 138, 853-860.	2.1	39
28	Economic evaluation of varicella vaccination in Spainâ€”Results from a dynamic model. Vaccine, 2006, 24, 6980-6989.	3.8	37
29	Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6â€“35â€¯months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres. Vaccine, 2019, 37, 1876-1884.	3.8	37
30	Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis among children aged less than 5Âyears in six European countries. European Journal of Pediatrics, 2011, 170, 213-222.	2.7	36
31	Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1231-1238.	3.6	36
32	Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infectious Diseases, The, 2006, 6, 805-812.	9.1	35
33	Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged â‰¥50 years: A randomised non-inferiority clinical trial. Vaccine, 2015, 33, 789-795.	3.8	35
34	Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clinical Microbiology and Infection, 2010, 16, 948-954.	6.0	34
35	Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine, 2019, 37, 2482-2493.	3.8	34
36	Data Resource Profile: The Valencia Health System Integrated Database (VID). International Journal of Epidemiology, 2020, 49, 740-741e.	1.9	34

#	Article	IF	Citations
37	ROTAVIRUS GASTROENTERITIS AMONG CHILDREN UNDER FIVE YEARS OF AGE IN VALENCIA, SPAIN. Pediatric Infectious Disease Journal, 2006, 25, 455-457.	2.0	31
38	Risk factors for invasive disease among children in Spain. Journal of Infection, 2004, 48, 320-329.	3.3	30
39	The impact of childhood acute rotavirus gastroenteritis on the parentsâ€™ quality of life: prospective observational study in European primary care medical practices. BMC Pediatrics, 2012, 12, 58.	1.7	30
40	A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants. Vaccine, 2014, 32, 5206-5211.	3.8	30
41	Depression in women suffering perinatal loss. International Journal of Gynecology and Obstetrics, 1998, 62, 149-153.	2.3	28
42	Influence of health literacy on acceptance of influenza and pertussis vaccinations: a cross-sectional study among Spanish pregnant women. BMJ Open, 2018, 8, e022132.	1.9	28
43	Effectiveness of rotavirus vaccines, licensed but not funded, against rotavirus hospitalizations in the Valencia Region, Spain. BMC Infectious Diseases, 2015, 15, 92.	2.9	27
44	Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age. Pediatric Infectious Disease Journal, 2016, 35, e113-e123.	2.0	27
45	Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine, 2011, 29, 9640-9648.	3.8	26
46	Epidemiology and economic impact of varicella in immunocompetent children in Spain.. Vaccine, 2003, 21, 3236-3239.	3.8	25
47	Epidemiology of Herpes Zoster Infection among Patients Treated in Primary Care Centres in the Valencian Community (Spain). BMC Family Practice, 2010, 11, 33.	2.9	25
48	Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine, 2018, 36, 347-354.	3.8	25
49	Economic evaluation of meningococcal vaccines: considerations for the future. European Journal of Health Economics, 2020, 21, 297-309.	2.8	25
50	Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population. Journal of Infectious Diseases, 2014, 209, 12-23.	4.0	24
51	Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009â€“2014. BMC Infectious Diseases, 2020, 20, 905.	2.9	24
52	Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain. BMC Public Health, 2010, 10, 469.	2.9	23
53	Impact of postherpetic neuralgia: A six year population-based analysis on people aged 50 years or older. Journal of Infection, 2018, 77, 131-136.	3.3	23
54	Risk and impact of herpes zoster among COPD patients: a population-based study, 2009â€“2014. BMC Infectious Diseases, 2018, 18, 203.	2.9	23

#	Article	IF	Citations
55	13-valent Pneumococcal Conjugate Vaccine Given With Meningococcal Câ€“Tetanus Toxoid Conjugate and Other Routine Pediatric Vaccinations. Pediatric Infectious Disease Journal, 2012, 31, 392-399.	2.0	22
56	Effectiveness of the WC/rBS oral cholera vaccine in the prevention of traveler's diarrhea. Human Vaccines and Immunotherapeutics, 2013, 9, 692-698.	3.3	22
57	â€œKnowledge and attitudes of Spanish adolescent girls towards human papillomavirus infection: where to intervene to improve vaccination coverageâ€• BMC Public Health, 2014, 14, 490.	2.9	22
58	Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Human Vaccines and Immunotherapeutics, 2019, 15, 2865-2872.	3.3	22
59	Nosocomial Rotavirus Gastroenteritis in Spain. Pediatric Infectious Disease Journal, 2010, 29, 23-27.	2.0	21
60	Circovirus and impact of temporary withdrawal of rotavirus vaccines in Spain. Hum Vaccin, 2011, 7, 798-799.	2.4	21
61	ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENINGOCOCCAL-C CONJUGATED VACCINE IN THE SECOND YEAR OF LIFE. Pediatric Infectious Disease Journal, 2010, 29, 768-770.	2.0	20
62	Intussusception following rotavirus vaccination in the Valencia Region, Spain. Human Vaccines and Immunotherapeutics, 2015, 11, 1848-1852.	3.3	20
63	Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system. Public Health, 2016, 135, 66-74.	2.9	20
64	Cost analysis of a vaccination strategy for respiratory syncytial virus (RSV) in a network model. Mathematical and Computer Modelling, 2010, 52, 1016-1022.	2.0	19
65	Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial. Vaccine, 2017, 35, 395-402.	3.8	19
66	Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50ÂYears or Older: A Prospective Cohort Study. Advances in Therapy, 2021, 38, 3325-3341.	2.9	19
67	Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine, 2011, 29, 6042-6048.	3.8	18
68	Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season. Vaccine, 2017, 35, 7331-7338.	3.8	18
69	Long-term impact of self-financed rotavirus vaccines on rotavirus-associated hospitalizations and costs in the Valencia Region, Spain. BMC Infectious Diseases, 2017, 17, 267.	2.9	18
70	Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine, 2019, 37, 6262-6267.	3.8	18
71	The impact of childhood RSV infection on children's and parents' quality of life: a prospective multicenter study in Spain. BMC Infectious Diseases, 2021, 21, 924.	2.9	18
72	Ibuprofen prophylaxis for adverse reactions to diphtheria-tetanus-pertussis vaccination: a randomized trial. Current Therapeutic Research, 1998, 59, 579-588.	1.2	17

#	Article	IF	Citations
73	Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1â€“11-year-old children. Vaccine, 2005, 23, 5099-5105.	3.8	17
74	Rotavirus, vaccine failure or diagnostic error?. Vaccine, 2016, 34, 5912-5915.	3.8	17
75	Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study. PLoS ONE, 2018, 13, e0204799.	2.5	17
76	Influenza Vaccine Effectiveness in Preventing Influenza A(H3N2)-Related Hospitalizations in Adults Targeted for Vaccination by Type of Vaccine: A Hospital-Based Test-Negative Study, 2011â€“2012 A(H3N2) Predominant Influenza Season, Valencia, Spain. PLoS ONE, 2014, 9, e112294.	2.5	17
77	Integrating molecular point-of-care testing for influenza into primary care: a mixed-methods feasibility study. British Journal of General Practice, 2020, 70, e555-e562.	1.4	17
78	Gut Microbiota in Children Vaccinated With Rotavirus Vaccine. Pediatric Infectious Disease Journal, 2012, 31, 1300-1302.	2.0	16
79	Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10â€“17 years of age: Results from a randomised, controlled, double-blind trial. Vaccine, 2013, 31, 6136-6143.	3.8	16
80	Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine, 2013, 31, 4765-4774.	3.8	16
81	MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: Comparative effectiveness using the Valencia health care information system. Vaccine, 2013, 31, 3995-4002.	3.8	16
82	Phase <scp>II</scp>, randomized, open, controlled study of <scp>AS</scp>03â€adjuvanted H5N1 preâ€pandemic influenza vaccine in children aged 3 to 9Âyears: followâ€up of safety and immunogenicity persistence at 24Âmonths postâ€vaccination. Influenza and Other Respiratory Viruses, 2015, 9, 68-77.	3.4	16
83	Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe â€“ Results from the DRIVE EU study platform. Vaccine, 2021, 39, 3964-3973.	3.8	16
84	Epidemiology of Invasive Streptococcus pneumoniae Infections in Children in Spain, 1996â€“1998. Journal of Infection, 2002, 45, 139-143.	3.3	16
85	Impact of Non-routine Vaccination on the Incidence of Invasive Haemophilus influenzae Type b (Hib) Disease: Experience in the Autonomous Region of Valencia, Spain. Journal of Infection, 2001, 42, 257-260.	3.3	15
86	Intradermal and virosomal influenza vaccines for preventing influenza hospitalization in the elderly during the 2011â€“2012 influenza season: A comparative effectiveness study using the Valencia health care information system. Vaccine, 2014, 32, 5447-5454.	3.8	15
87	Using random networks to study the dynamics of respiratory syncytial virus (RSV) in the Spanish region of Valencia. Mathematical and Computer Modelling, 2011, 54, 1650-1654.	2.0	14
88	Incidence of pertussis in persons â‰¥15 years of age in Valencia, Spain: seroprevalence of antibodies to pertussis toxin (PT) in children, adolescents and adults. Journal of Infection, 2004, 49, 242-247.	3.3	13
89	Seroprevalence of Varicella Among Children and Adolescents in Valencia, Spain: Reliability of the Parentâ€™s Reported History and the Medical File for Identification of Potential Candidates for Vaccination. Hum Vaccin, 2005, 1, 204-206.	2.4	13
90	It is time to abandon â€œExpected bladder capacity.â€•Systematic review and new models for children's normal maximum voided volumes. Neurourology and Urodynamics, 2014, 33, 1092-1098.	1.5	13

#	Article	IF	Citations
91	Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. Cmaj, 2017, 189, E1276-E1285.	2.0	13
92	Epidemiological Pattern of Meningococcal Disease in Valencia, Spain. Impact of a Mass Immunization Campaign With Meningococcal C Polysaccharide Vaccine. Scandinavian Journal of Infectious Diseases, 2001, 33, 581-584.	1.5	12
93	Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain. Vaccine, 2013, 31, 5486-5494.	3.8	12
94	Lack of impact of rotavirus vaccines on seizure-related hospitalizations in children under 5Âyears old in Spain. Human Vaccines and Immunotherapeutics, 2018, 14, 1534-1538.	3.3	12
95	Drivers for human papillomavirus vaccination in Valencia (Spain). Gaceta Sanitaria, 2018, 32, 454-458.	1.5	12
96	Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1â€“11 years. Vaccine, 2010, 28, 4411-4415.	3.8	11
97	Comparison between diagnosis and treatment of community-acquired pneumonia in children in various medical centres across Europe with the United States, United Kingdom and the World Health Organization guidelines. Pneumonia (Nathan Qld), 2016, 8, 5.	6.1	11
98	Operational lessons learned in conducting a multi-country collaboration for vaccine safety signal verification and hypothesis testing: The global vaccine safety multi country collaboration initiative. Vaccine, 2018, 36, 355-362.	3.8	11
99	Immunogenicity and Reactogenicity of a Combined Adsorbed Tetanus Toxoid, Low Dose Diphtheria Toxoid, Five Component Acellular Pertussis and Inactivated Polio Vaccine in Six-Year-Old Children. Pediatric Infectious Disease Journal, 2005, 24, 219-224.	2.0	10
100	Ethical considerations of universal vaccination against human papilloma virus. BMC Medical Ethics, 2014, 15, 29.	2.4	10
101	Predictors of influenza severity among hospitalized adults with laboratory confirmed influenza: Analysis of nine influenza seasons from the Valencia region, Spain. Influenza and Other Respiratory Viruses, 2022, 16, 862-872.	3.4	10
102	Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine Manufactured With Recombinant Human Albumin. Pediatric Infectious Disease Journal, 2012, 31, 1166-1172.	2.0	9
103	Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17. Eurosurveillance, 2018, 23, .	7.0	9
104	Uncertainty and sensitivity of the sexual behavior changes to the current human papillomavirus vaccination campaign in Spain. Mathematical Methods in the Applied Sciences, 2021, 44, 7845-7857.	2.3	9
105	Feasibility of Point-of-Care Testing for Influenza Within a National Primary Care Sentinel Surveillance Network in England: Protocol for a Mixed Methods Study. JMIR Research Protocols, 2019, 8, e14186.	1.0	9
106	Role of age and birth month in infants hospitalized with RSVâ€confirmed disease in the Valencia Region, Spain. Influenza and Other Respiratory Viruses, 2022, 16, 328-339.	3.4	9
107	Evidencias cientÃficas disponibles sobre la seguridad de las vacunas. Vacunas, 2011, 12, 3-34.	2.0	8
108	Impact of a Gender-Neutral HPV Vaccination Program in Men Who Have Sex with Men (MSM). International Journal of Environmental Research and Public Health, 2021, 18, 963.	2.6	8

#	Article	IF	Citations
109	EpidemiologÃa e impacto de la otitis media aguda en la Comunidad Valenciana. Anales De PediatrÃa, 2004, 60, 125-132.	0.2	8
110	Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain). BMC Infectious Diseases, 2014, 14, 280.	2.9	7
111	Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season. Journal of Clinical Virology, 2016, 84, 32-38.	3.1	7
112	Random Network Models to Predict the Long-Term Impact of HPV Vaccination on Genital Warts. Viruses, 2017, 9, 300.	3.3	7
113	Clinical and laboratory features of children with community-acquired pneumonia are associated with distinct radiographic presentations. European Journal of Pediatrics, 2018, 177, 1111-1120.	2.7	7
114	Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers. Pediatric Infectious Disease Journal, 2019, 38, 317-322.	2.0	7
115	Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60â€‰years or older, Valencia Region, Spain, 2017/18 influenza season. Eurosurveillance, 2019, 24, .	7.0	7
116	Safety and tolerability of cell culture-derived and egg-derived trivalent influenza vaccines in 3 to <18-year-old children and adolescents at risk of influenza-related complications. International Journal of Infectious Diseases, 2016, 49, 171-178.	3.3	6
117	What have we learnt about rotavirus in Spain in the last 10 years?. Anales De PediatrÃa (English) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.2	6
118	A tool for early estimation of influenza vaccination coverage in Spanish general population and healthcare workers in the 2018â€“19 season: the GripÃ³metro. BMC Public Health, 2022, 22, 825.	2.9	6
119	MF59â„¢-adjuvanted seasonal influenza vaccine in young children. Expert Review of Vaccines, 2011, 10, 1519-1528.	4.4	5
120	Letter to the editor regarding â€œThe role of age-sex interaction in the development of post-herpetic neuralgiaâ€• Human Vaccines and Immunotherapeutics, 2018, 14, 906-908.	3.3	5
121	Using Point of Care Testing to estimate influenza vaccine effectiveness in the English primary care sentinel surveillance network. PLoS ONE, 2021, 16, e0248123.	2.5	5
122	Adverse Events after Polysaccharide meningococcal A&C Vaccine. Scandinavian Journal of Infectious Diseases, 1998, 30, 636-638.	1.5	4
123	Spatio-temporal impact of self-financed rotavirus vaccination on rotavirus and acute gastroenteritis hospitalisations in the Valencia region, Spain. BMC Infectious Diseases, 2020, 20, 656.	2.9	4
124	Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season. International Journal of Environmental Research and Public Health, 2021, 18, 1129.	2.6	4
125	On the Elimination of Infections Related to Oncogenic Human Papillomavirus: An Approach Using a Computational Network Model. Viruses, 2021, 13, 906.	3.3	4
126	Retrospective screening for SARSâ€CoVâ€2 among influenzaâ€like illness hospitalizations: 2018â€“2019 and 2019â€“2020 seasons, Valencia region, Spain. Influenza and Other Respiratory Viruses, 2022, 16, 166-171.	3.4	4

#	Article	IF	Citations
127	Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults. Human Vaccines and Immunotherapeutics, 2022, 18, 1-9.	3.3	4
128	Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009â€“2017. Vaccine, 2022, 40, 316-324.	3.8	4
129	A RANDOMIZED, MULTICENTER, OPEN-LABEL CLINICAL TRIAL TO ASSESS THE ANAMNESTIC IMMUNE RESPONSE 4 TO 8 YEARS AFTER A PRIMARY HEPATITIS B VACCINATION SERIES. Pediatric Infectious Disease Journal, 2010, 29, 972-974.	2.0	3
130	Vaccine coverage estimation using a computerized vaccination registry with potential underreporting and a seroprevalence study. Vaccine, 2015, 33, 2183-2188.	3.8	3
131	Pertussis in adults with persistent cough: a prospective follow up study in primary care. Procedia in Vaccinology, 2009, 1, 73-80.	0.4	2
132	Calendario vacunal de la AsociaciÃ³n EspaÃ±ola de PediatrÃa 2009. Vacunas, 2009, 10, 88-97.	2.0	2
133	Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-NaÃ¯ve Children. Pediatric Infectious Disease Journal, 2019, 38, 203-210.	2.0	2
134	Risk Measurement of Perinatal and Neonatal Morbidity Characteristics and Applicability of GAIA Case Definitions: Results and Lessons Learnt of a Hospital-Based Prospective Cohort Study in the Valencia Region (2019â€“2020). International Journal of Environmental Research and Public Health, 2022, 19, 7132.	2.6	2
135	Encefalitis centroeuropea o transmitida por garrapatas. Vacunas, 2002, 3, 154-157.	2.0	1
136	Recomendaciones de vacunaciÃ³n de la AsociaciÃ³n EspaÃ±ola de PediatrÃa 2008. Vacunas, 2008, 9, 80-85.	2.0	1
137	Studying the Herd Immunity Effect of the Varicella Vaccine in the Community of Valencia, Spain. Lecture Notes in Computer Science, 2016, , 38-46.	1.3	1
138	Infecciones por virus respiratorio sincitial en adultos diagnosticados en la Comunidad Valenciana. Revista Clinica Espanola, 2016, 216, 508-510.	0.6	1
139	Herpes Zoster-Associated Resources Consumption In Chronic Obstructive Pulmonary Disease Patients. Value in Health, 2016, 19, A603-A604.	0.3	1
140	Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination. Vaccine, 2017, 35, 2949-2954.	3.8	1
141	Sistemas de informaciÃ³n en atenciÃ³n primaria: Â¿debemos codificar con la CIE-9-MC?. Atencion Primaria, 2003, 31, 519-523.	1.4	1
142	The situation of infection in the elderly in Spain: a multidisciplinary opinion document. Revista Espanola De Quimioterapia, 2020, 33, 327-349.	1.3	1
143	Vacuna del meningococo, Â¿necesidad de revacunaciones?. Anales De Pediatria Continuada, 2003, 1, 166-168.	0.1	0
144	Economic Burden Of Herpes Zoster In Spain. Value in Health, 2017, 20, A785.	0.3	0

#	Article	IF	Citations
145	Letter to the editor regarding “Rotavirus infection beyond the gut” . Infection and Drug Resistance, 2019, Volume 12, 707-708.	2.7	0
146	InmunizaciÃ³n: saltos al futuro. Vacunas combinadas (I). Atencion Primaria, 2003, 31, 453-457.	1.4	0
147	InmunizaciÃ³n: saltos al futuro. Vacunas combinadas (II). Atencion Primaria, 2003, 31, 601-605.	1.4	0
148	Incidence of herpes zoster and its complications in â‰¥ 50-year-old Spanish adults: A prospective cohort study. Vacunas, 2022, , .	2.0	0
149	Encuesta sobre el uso racional de antibiÃ³ticos en atenciÃ³n primaria. Anales De PediatrÃa, 2003, 58, 10-16.	0.2	0
150	AtenciÃ³n a neonatos en una unidad de urgencias pediÃ¡tricas. Anales De PediatrÃa, 2003, 59, 54-58.	0.2	0